Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo.

× No keyword cloud information.

11 in total

1. TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer.

Authors: Alexandre Ivagnès; Meriem Messaoudene; Gautier Stoll; Bertrand Routy; Aurélie Fluckiger; Takahiro Yamazaki; Kristina Iribarren; Connie P M Duong; Laetitia Fend; Anne Caignard; Isabelle Cremer; Axel LeCesne; Julien Adam; Charles Honoré; Olivier Mir; Loïc Chaigneau; Anne Berger; Pierre Validire; Christos Christidis; Valérie Le Brun-Ly; Mark J Smyth; Xavier Mariette; Benoît L Salomon; Guido Kroemer; Sylvie Rusakiewicz; Laurence Zitvogel
Journal: Oncoimmunology Date: 2017-10-11 Impact factor: 8.110

Review 2. Immune modulation by dendritic-cell-based cancer vaccines.

Authors: Chaitanya Kumar; Sakshi Kohli; Poonamalle Parthasarathy Bapsy; Ashok Kumar Vaid; Minish Jain; Venkata Sathya Suresh Attili; Bandana Sharan
Journal: J Biosci Date: 2017-03 Impact factor: 1.826

Review 3. Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment.

Authors: Patrick A Ott; Sylvia Adams
Journal: Immunotherapy Date: 2011-02 Impact factor: 4.196

4. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.

Authors: Nicolas Larmonier; Nona Janikashvili; Collin James LaCasse; Claire Billerey Larmonier; Jessica Cantrell; Elaine Situ; Tamara Lundeen; Bernard Bonnotte; Emmanuel Katsanis
Journal: J Immunol Date: 2008-11-15 Impact factor: 5.422

5. Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy.

Authors: Ritika Jaini; Patricia Rayman; Peter A Cohen; James H Finke; Vincent K Tuohy
Journal: Int J Cancer Date: 2013-10-08 Impact factor: 7.396

Review 6. Immunological off-target effects of imatinib.

Authors: Laurence Zitvogel; Sylvie Rusakiewicz; Bertrand Routy; Maha Ayyoub; Guido Kroemer
Journal: Nat Rev Clin Oncol Date: 2016-03-31 Impact factor: 66.675

7. Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients.

Authors: S Thiant; M M Moutuou; P Laflamme; R Sidi Boumedine; D M Leboeuf; L Busque; J Roy; M Guimond
Journal: Blood Cancer J Date: 2017-04-07 Impact factor: 11.037

8. Oncogenic kinase inhibition limits Batf3-dependent dendritic cell development and antitumor immunity.

Authors: Benjamin D Medina; Mengyuan Liu; Gerardo A Vitiello; Adrian M Seifert; Shan Zeng; Timothy Bowler; Jennifer Q Zhang; Michael J Cavnar; Jennifer K Loo; Nesteene J Param; Joanna H Maltbaek; Ferdinand Rossi; Vinod Balachandran; Ronald P DeMatteo
Journal: J Exp Med Date: 2019-04-18 Impact factor: 14.307

9. Cytokine Syntheses by T-Cell Subsets From Chronic Myeloid Leukemia Patients: Relationship Between Pre-Treatment Levels and Response to Imatinib Therapy.

Authors: Inaam B Hassan; Sheela Benedict; Jorgen Kristensen
Journal: J Hematol Date: 2018-09-01

Review 10. Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation.

Authors: Pier Edoardo Rovatti; Valentina Gambacorta; Francesca Lorentino; Fabio Ciceri; Luca Vago
Journal: Front Immunol Date: 2020-02-25 Impact factor: 7.561